CN107727728A - A kind of iTRAQ marks the application in osteoarthritis - Google Patents

A kind of iTRAQ marks the application in osteoarthritis Download PDF

Info

Publication number
CN107727728A
CN107727728A CN201711169091.1A CN201711169091A CN107727728A CN 107727728 A CN107727728 A CN 107727728A CN 201711169091 A CN201711169091 A CN 201711169091A CN 107727728 A CN107727728 A CN 107727728A
Authority
CN
China
Prior art keywords
str
itraq
ort
marks
control group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711169091.1A
Other languages
Chinese (zh)
Inventor
于思创
王海云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanning Keicheng Mdt Infotech Ltd
Original Assignee
Nanning Keicheng Mdt Infotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Keicheng Mdt Infotech Ltd filed Critical Nanning Keicheng Mdt Infotech Ltd
Priority to CN201711169091.1A priority Critical patent/CN107727728A/en
Publication of CN107727728A publication Critical patent/CN107727728A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/105Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The invention discloses a kind of iTRAQ to mark the application in osteoarthritis, 2. 1. preparation of samples extracts STR/ort model groups and control group serum, isometric mixing is distinguished by two groups, using acetone precipitation will quantitatively 3. STR/ort model groups and control group serum differential protein press difference ratio after protein precipitation>1.2 or<0.8, the peptide hop count identified is at least>2 is selected, surveys function and possible interaction that they are played in OA grid, screens candidate's OA marks.The present invention carries out the confirmation of mark by crowd's sample, assess these OA candidate markers diagnosis OA value and analyze its correlation with clinic, it is proposed their feasibilities in terms of the clinical practices such as OA prevention, early diagnosis, and its meaning in crowd's bony articulation health early warning.

Description

A kind of iTRAQ marks the application in osteoarthritis
Technical field
The present invention relates to genetic transcription group and proteomics field, especially a kind of iTRAQ marks combine MALDI- Applications of the TOF MS-MS in osteoarthritis STR-ort models.
Background technology
Osteoarthritis (osteoarthritis, OA) is also known as degenerative osteoarthropathy, is one of most common joint diseases, The pain slowly developed in joint, stiff, enlargement are mainly shown as, with joint function disturbance, or even disabled [1-2] occurs.OA Pathogenesis be joint by science of heredity, biology and Mechanics of Machinery event(Such as heredity, metabolic disorder, strain, wound)'s Collective effect, induces cell and matrix changes in morphology, biomethanics, molecules etc., causes articular cartilage thin Born of the same parents, the degraded of extracellular matrix and subchondral bone and synthesis are uneven.Its final result is the softening of cartilage cell, fibrosis, ulcer And lose, after the protective effect of cartilage is lost, subchondral bone hardens, ivory, ultimately results under spur and cartilage The formation of bone cyst.
OA can involve the multiple joints of whole body, and its illness rate increases and increased with the age, especially endangers senior health and fitness, and give Society brings heavy burden.OA illness rate is up to more than 50% in over-65s crowd at present, and more than 75 years old in crowd, This numerical value can reach 80% or so.The survey data in the U.S. shows that OA causes more than 50 years old male's disablement No. 2 killer, is only second to angiocardiopathy [5].With the world and the acceleration of Chinese society aging population, OA increasingly into For doctors and patients or even the hot topic of social concerns.
At present, the diagnosis to OA relies primarily on clinical symptoms, imaging data and arthroscopy etc., wherein, after Both have very big value for clear and definite joint part histopathologic change situation.The change of x-ray is evaluation OA progress in iconography Common method, but it still has certain limitation, and its specificity and sensitiveness are poor.Studied and sent out by Pathologic specimen Existing, when X lines are acted normally, articular cartilage may also seriously be involved;Once there is the change of X lines, disease in patient Progressive stage [6-7] is often in, the normal function in joint and the quality of life of patient have been subjected to serious, irreversible Influence.Magnetic resonance imaging (MRI) is high to soft tissue resolution, can be imaged from arbitrary face and multi-parameter, multi-sequence im-aging, The change situation of cartilage can be directly displayed, contributes to OA early diagnosis, but due to expensive, it is difficult to for a wide range of Disease assessment and generaI investigation.In addition, arthroscope is the best means for evaluating damaged articular cartilage, is considered as that diagnosis joint is soft The goldstandard of damaged bone, it can directly observe swelling and the ulceration situation of hyaline cartilage.But it is invasive due to inspection, and The change of cartilage deep layer and subchondral bone matter can not be shown, its clinical practice is also restrained.Therefore, probe into effective, cheap And minimally invasive detection methods come detect subclinical OA and monitor lesion progress, to early diagnosis and effectively preventing and treating OA have Important meaning.
With the development of molecular biology and the raising of research meanses, researcher attempts sight being placed on available for clinical pre- Survey and assess OA biology blood serum designated object aspect [8-9].OA blood serum designated object, it is the molecule thing of joint tissue matrix Matter or segment, they are released into blood in tissue synthesis and the metabolic process decomposed, can inhaled by enzyme linked immunological Attached method (ELISA) or radioimmunology are measured, and are suitably applied in health examination and Mass screening, and the bone of crowd is closed It is significant to save healthy early warning.Detection at present, analysis and determination disease blood serum mark rely primarily on proteomic techniques, use Proteomic techniques illustrate the mutual of the change of disease marker protein expression level and disease development different phase Relation and its rule, it has also become solve the best approach [10-11] of disease early diagnosis problem.And mass-spectrometric technique is albumen The core of omics technology, the iTRAQ of new development over the past two years(isobaric tags for relative and absolute Quantification, iTRAQ)Mark combines MALDI-TOF MS/MS technologies, is provided for the discovery and identification of disease marker Qualitative, quantitative information [12], are newest in disease marker screening study and most strong means.
Therefore, MALDI-TOF MS/MS scientific discoveries and identification OA marker proteins are combined using iTRAQ marks, is mesh Preceding energy let us screens from thousands of haemocyanins to be existed in serum really, and and can indicates OA blood serum designated object Ideal scheme.However, because mass-spectrometric technique has high sensitivity and high-resolution characteristic, its obtained data letter Breath is often magnanimity, and in these differential proteins with respect to magnanimity, key necessary to both being formed containing OA sexually revises, Containing only because of the unstability of disease genome and caused by with sexually revising [13].In addition, human diseases is also extremely complex, Old OA patient more likely suffers from the disease of multiple organ system simultaneously, even if being all the patient for only suffering from OA, because of age, sex, body Matter, heredity etc. are different, have an impact to the express spectra of haemocyanin.How by those influence OA occurrence and development it is key Molecule is the significant challenge of current research from non-OA specificity, unstability and with being identified in sexually revising.
To solve these key issues, this project plan first iTRAQ marks combine MALDI-TOF MS/MS find and The technology of identification disease marker albumen is applied to osteoarthritis STR/ort models.STR/ort models are that a kind of spontaneous OA is moved Thing model [14], the Histological assessment of its articular cartilage show, the OA incidences of disease of STR/ort mouse and the order of severity with the age by Cumulative to add, irreversible change appears in final stage, and degenerative process is very similar to human osteoarthritic, is preferably to grind Study carefully model [15-19] inside OA onsets and progress.In addition, STR/ort mouse models are in kind, strain, sex, age, body Weight, activity, even health status, heredity and microorganism etc. the indifference opposite sex, temperature, humidity, illumination, noise, feed etc. Rearing conditions are also identical, are the consistent cast materials of a kind of disease conditions [20-21], suitable for OA disease marker discovery phases Research, can help to find specific OA candidate markers.
Biomarker has to pass through discovery or identification(Discovery), checking(Verification), confirm (Validation)Three steps, then just enter clinical examination etc. deeper into stage [22].Therefore, this project will continue to test Demonstrate,prove the OA serum candidate markers found in STR/ort models, including its differential expression situation and OA specificity issues.We Intend carrying out the expression checking of candidate markers in STR/ort mouse and OA patients serums, determine differential expression trend, adopt simultaneously Collect OA patient articular's synovia, the specificity issues of analysis candidate markers and OA lesions, make OA marks in OA clinical samples Also it is verified.Then, our quantitative detections by deep progress OA marks in patients serum's sample, itself and OA diseases are analyzed The relation of journey, and establish OA diagnosing models, calculate OA marks diagnosis OA sensitivity, specificity, positive predictive value and Negative predictive value, propose their feasibilities in terms of the clinical practices such as OA prevention, early diagnosis, disease course prediction.
Therefore, based on iTRAQ marks combine MALDI-TOF MS/MS technologies, spontaneous OA animal models are utilized STR/ort mouse, find and identification OA serum differentially expressed proteins, and to be verified they are specific and poor in OA clinical samples After different expression, then go deep into the research of OA diagnosing models, confirm prevention, early diagnosis, the course of disease of the OA marks in OA Effect in terms of the clinical practices such as prediction.This project provides the early warning for crowd's bony articulation health new thinking.
ITRAQ mark combine MALDI-TOF MS/MS in osteoarthritis STR/ort models are the research can not or Scarce composition part, a kind of iTRAQ marks of the present invention combine MALDI-TOF MS-MS in osteoarthritis STR-ort models The technical scheme of application, have no identical through retrieving domestic pharmaceutical industry industry.
The content of the invention
It is an object of the invention to provide a kind of iTRAQ marks to combine MALDI-TOF MS-MS in osteoarthritis STR-ort Application in model.
This iTRAQ marks combine applications of the MALDI-TOF MS-MS in osteoarthritis STR-ort models,
Comprise the steps of:
1. preparation of samples:STR/ort model mices and each 10 of control mice, by the raising requirement raising of cleaning grade animal half In barrier system;Support to 20 week old(Adult), every mouse takes blood 0.9-1.5 mL through eyeball;After 4 DEG C of blood sample stands 1 h, 5000 r/min centrifuge 5 min, take supernatant, load 0.2 mL EP pipes by 50 μ L/ pipes, carry out mark, -80 DEG C of preservations are standby With;
2. STR/ort model groups and control group serum are extracted, by two groups of isometric mixing respectively, using acetone precipitation by albumen It is quantitative after matter precipitation, make every group containing about 100ug total proteins, carry out carrying out pancreatin enzymolysis, reductive alkylation, iTRAQ marks successively Strictly carried out Deng, process in accordance with iTRAQ kit specifications;STR/ort model groups and control group serum after iTRAQ is marked Enzymolysis product mixed in equal amounts, after carrying out one-dimensional SCX and two-dimentional nano-LC chromatographic isolations, into spectrometer analysis;
3. STR/ort model groups and control group serum differential protein press difference ratio>1.2 or<0.8, the peptide hop count identified is extremely It is few>2 is selected, utilizes Gene Ontology Consortium, Kyoto Encyclopedia of Genes and The databases such as Genomes, protein-protein interaction prediction database are carried out to entering sortilin Analysis, function and possible interaction that they play in OA grid are predicted, screens candidate's OA marks.
Invention beneficial effect:
The present invention intends by osteoarthritis STR/ort models, and MALDI-TOF MS/MS scientific discoveries are combined using iTRAQ marks OA serum differentially expressed proteins, analyzing them using bioinformatics technique may performance in the signal network of OA occurrence and development Function and interaction;It is equal in osteoarthritis STR/ort models and OA patients serums, lesion knuckle synovia to filter out those Candidate serum OA marks specific expressed and that differential expression trend is consistent;Mark is carried out really by crowd's sample again Recognize, assess these OA candidate markers diagnosis OA value and analyze itself and clinical correlation, propose they OA prevention, Feasibility in terms of the clinical practices such as early diagnosis, and its meaning in crowd's bony articulation health early warning.
Embodiment
Embodiment:
This iTRAQ marks combine applications of the MALDI-TOF MS-MS in osteoarthritis STR-ort models,
Comprise the steps of:
1. preparation of samples:STR/ort model mices and each 10 of control mice, by the raising requirement raising of cleaning grade animal half In barrier system;Support to 20 week old(Adult), every mouse takes blood 0.9-1.5 mL through eyeball;After 4 DEG C of blood sample stands 1 h, 5000 r/min centrifuge 5 min, take supernatant, load 0.2 mL EP pipes by 50 μ L/ pipes, carry out mark, -80 DEG C of preservations are standby With;
2. STR/ort model groups and control group serum are extracted, by two groups of isometric mixing respectively, using acetone precipitation by albumen It is quantitative after matter precipitation, make every group containing about 100ug total proteins, carry out carrying out pancreatin enzymolysis, reductive alkylation, iTRAQ marks successively Strictly carried out Deng, process in accordance with iTRAQ kit specifications;STR/ort model groups and control group serum after iTRAQ is marked Enzymolysis product mixed in equal amounts, after carrying out one-dimensional SCX and two-dimentional nano-LC chromatographic isolations, into spectrometer analysis;
3. STR/ort model groups and control group serum differential protein press difference ratio>1.2 or<0.8, the peptide hop count identified is extremely It is few>2 is selected, utilizes Gene Ontology Consortium, Kyoto Encyclopedia of Genes and The databases such as Genomes, protein-protein interaction prediction database are carried out to entering sortilin Analysis, function and possible interaction that they play in OA grid are predicted, screens candidate's OA marks.
The foregoing is only a preferred embodiment of the present invention, but protection scope of the present invention be not limited thereto, Any one skilled in the art the invention discloses technical scope in, technique according to the invention scheme and its Inventive concept is subject to equivalent substitution or change, should all be included within the scope of the present invention.

Claims (1)

1. a kind of iTRAQ marks the application in osteoarthritis, it is characterised in that:Comprise the steps of:
1. preparation of samples:STR/ort model mices and each 10 of control mice, by the raising requirement raising of cleaning grade animal half In barrier system;Support to 20 week old(Adult), every mouse takes blood 0.9-1.5 mL through eyeball;After 4 DEG C of blood sample stands 1 h, 5000 r/min centrifuge 5 min, take supernatant, load 0.2 mL EP pipes by 50 μ L/ pipes, carry out mark, -80 DEG C of preservations are standby With;
2. STR/ort model groups and control group serum are extracted, by two groups of isometric mixing respectively, using acetone precipitation by albumen It is quantitative after matter precipitation, make every group containing about 100ug total proteins, carry out carrying out pancreatin enzymolysis, reductive alkylation, iTRAQ marks successively Strictly carried out Deng, process in accordance with iTRAQ kit specifications;STR/ort model groups and control group serum after iTRAQ is marked Enzymolysis product mixed in equal amounts, after carrying out one-dimensional SCX and two-dimentional nano-LC chromatographic isolations, into spectrometer analysis;
3. STR/ort model groups and control group serum differential protein press difference ratio>1.2 or<0.8, the peptide hop count identified is extremely It is few>2 is selected, utilizes Gene Ontology Consortium, Kyoto Encyclopedia of Genes and The databases such as Genomes, protein-protein interaction prediction database are carried out to entering sortilin Analysis, function and possible interaction that they play in OA grid are predicted, screens candidate's OA marks.
CN201711169091.1A 2017-11-22 2017-11-22 A kind of iTRAQ marks the application in osteoarthritis Pending CN107727728A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711169091.1A CN107727728A (en) 2017-11-22 2017-11-22 A kind of iTRAQ marks the application in osteoarthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711169091.1A CN107727728A (en) 2017-11-22 2017-11-22 A kind of iTRAQ marks the application in osteoarthritis

Publications (1)

Publication Number Publication Date
CN107727728A true CN107727728A (en) 2018-02-23

Family

ID=61217808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711169091.1A Pending CN107727728A (en) 2017-11-22 2017-11-22 A kind of iTRAQ marks the application in osteoarthritis

Country Status (1)

Country Link
CN (1) CN107727728A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104246507A (en) * 2012-03-26 2014-12-24 雀巢产品技术援助有限公司 Early biomarkers of age-related low-grade inflammation
WO2015136298A1 (en) * 2014-03-13 2015-09-17 Isis Innovation Limited Methods and system for determining the disease status of a subject
WO2016127035A1 (en) * 2015-02-05 2016-08-11 Duke University Methods of detecting osteoarthritis and predicting progression thereof
US20170030925A1 (en) * 2010-03-05 2017-02-02 The Curators Of The University Of Missouri Biomarkers of osteoarthritis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170030925A1 (en) * 2010-03-05 2017-02-02 The Curators Of The University Of Missouri Biomarkers of osteoarthritis
CN104246507A (en) * 2012-03-26 2014-12-24 雀巢产品技术援助有限公司 Early biomarkers of age-related low-grade inflammation
WO2015136298A1 (en) * 2014-03-13 2015-09-17 Isis Innovation Limited Methods and system for determining the disease status of a subject
WO2016127035A1 (en) * 2015-02-05 2016-08-11 Duke University Methods of detecting osteoarthritis and predicting progression thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AITANA BRAZA-BOÏLS ET AL.: "Analysis of early biochemical markers and regulation by tin protoporphyrin IX in a model of spontaneous osteoarthritis", 《EXPERIMENTAL GERONTOLOGY》 *
XIAOMIN SONG ET AL.: "iTRAQ Experimental Design for Plasma Biomarker Discovery", 《JOURNAL OF PROTEOME RESEARCH》 *
梁海波 等: "膝骨性关节炎差异表达蛋白血清标记物筛选:iTRAQ技术的重要性", 《中国组织工程研究》 *
梁海波: "同位素相对标记技术(iTRAQ)结合双向液相色谱与质谱联用技术应用于膝骨性关节炎血清差异蛋白的实验研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Similar Documents

Publication Publication Date Title
Pizzichini et al. Measuring airway inflammation in asthma: eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood
Zoltewicz et al. Characterization of antibodies that detect human GFAP after traumatic brain injury
Gordon‐Lipkin et al. Comparative quantitative clinical, neuroimaging, and functional profiles in children with acute flaccid myelitis at acute and convalescent stages of disease
CN103328501A (en) Novel biomarker and uses thereof in diagnosis, treatment of autism
EP3786305A1 (en) Biomarker for depression and use thereof
CN105705652B (en) Method for assisting in the differential diagnosis of stroke
Martin et al. Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: a systematic review and meta-analysis
JP2012073274A (en) Protein profile for osteoarthritis
Sun et al. Identification of proteomic signatures associated with COPD frequent exacerbators
Siroux et al. Trajectories of IgE sensitization to allergen molecules from childhood to adulthood and respiratory health in the EGEA cohort
CN107167610B (en) autism biomarker and detection kit thereof
Ren et al. Biochemical markers for the early identification of osteoarthritis: systematic review and meta-analysis
CN107655998A (en) A kind of iTRAQ marks the application method in osteoarthritis
Beydoun et al. Plasma neurofilament light as blood marker for poor brain white matter integrity among middle-aged urban adults
CN107907693A (en) A kind of foundation of OA markers
CN107727729A (en) A kind of method for building up of OA candidate markers diagnostic model
Zhang et al. A novel splice site variant in the POPDC3 causes autosomal recessive limb‐girdle muscular dystrophy type 26
CN107918014A (en) A kind of osteoarthritis marker confirms
CN107727728A (en) A kind of iTRAQ marks the application in osteoarthritis
Sandhu et al. Association of synovial fluid and urinary C2C-HUSA levels with surgical outcomes post-total knee arthroplasty
CN107643406A (en) A kind of osteoarthritis mark checking
Nigoro et al. Obesity with radiological changes or depression was associated with worse knee outcome in general population: a cluster analysis in the Nagahama study
CN110396538A (en) Migraine biomarker and application thereof
Pereira et al. Biomarkers for intervertebral disc and associated back pain: From diagnosis to disease prognosis and personalized treatment
Qu et al. Reproducible abnormalities and diagnostic generalizability of white matter in Alzheimer’s disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180223